DDInter1340 DDInter1747
Originally approved by the FDA in 1989, omeprazole is a _proton-pump inhibitor_, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approval was followed by the formulation of many other proton pump inhibitor drugs. Omeprazole is generally effective and well-tolerated, promoting its popular use in children and adults [FDA label].
Tasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD). Occurring commonly in blind individuals without light perception, this condition is often characterized by periods of night-time insomnia and day-time sleepiness. In blind individuals, a lack of light stimulation causes an extension of the 24-hour circadian cycle and can lead to progressively delayed sleep onset. By activating melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, tasimelteon has been shown to improve sleep by resynchronizing the circadian rhythm through its "non-photic" mechanism. Tasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010.
Omeprazole {u} (Compound) resembles {v} (Compound) Pantoprazole
Omeprazole {u} (Compound) resembles {v} (Compound) Esomeprazole
Omeprazole {u} (Compound) treats {v} (Disease) Barrett's esophagus
Omeprazole {u} (Compound) binds {v} (Gene) CYP1A2
Omeprazole {u} (Compound) upregulates {v} (Gene) TIPARP
Omeprazole {u} (Compound) palliates {v} (Disease) systemic scleroderma
Omeprazole {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C19 Inhibitors
Omeprazole {u} (Compound) downregulates {v} (Gene) THAP11
Omeprazole {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Omeprazole (Compound) resembles Pantoprazole (Compound)
Omeprazole (Compound) resembles Esomeprazole (Compound)
Omeprazole (Compound) treats Barrett's esophagus (Disease)
Omeprazole (Compound) binds CYP1A2 (Gene)
Omeprazole (Compound) upregulates TIPARP (Gene)
Omeprazole (Compound) palliates systemic scleroderma (Disease)
Omeprazole (Compound) is included by Cytochrome P450 2C19 Inhibitors (Pharmacologic Class)
Omeprazole (Compound) downregulates THAP11 (Gene)
Omeprazole (Compound) causes Alanine aminotransferase increased (Side Effect)